July 18, 2005 09:32 ET

FDA Panel Votes 5-2 Against Kit Form of NTP Test

MAYWOOD, N.J.--(CCNMatthews - Jul 18, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that on Friday, July 15, an FDA advisory panel voted 5-2 against approval of the kit form of the Company's NTP test (AlzheimAlert™). AlzheimAlert™ remains approved for sale in the U.S. as a laboratory testing service through the Company's clinical reference laboratory in New Jersey. NASDAQ halted NYMX trading on Friday during the panel meeting in order to maintain an orderly market.

"We are very pleased to have had the opportunity to present the results of the blinded 9 center trial which showed that 89.5% of clinical cases of probable AD had elevated NTP and 91% of definite non-AD had normal NTP levels," said Dr. Paul Averback, CEO of Nymox. "The panel, however, felt that more data was required for approval, including, for example, post-mortem verification and clarification of how to use the test results. We anticipate working with FDA towards fulfilling the further data requirements that the agency may have in conjunction with the panel suggestions."

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox currently markets AlzheimAlert™ as a CLIA-certified laboratory testing service in the U.S. and as a kit in the European Union as a result of its certification with a CE Mark. The Company has successfully completed two U.S. Phase 1-2 clinical trials for NX-1207, its drug for benign prostatic hyperplasia (BPH). The Company markets NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure. Nymox has a number of drugs in development for Alzheimer's disease, oncology, and infectious disease.

The Company will hold a teleconference call for shareholders at 4:30 p.m. today. Call 800-936-9669 after 12:00 p.m. EST for details.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX